menu
    • menu
    [{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"ABL Europe","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"ODI-2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Odimma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Odimma Therapeutics \/ ABL Europe","highestDevelopmentStatusID":"4","companyTruncated":"Odimma Therapeutics \/ ABL Europe"},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"Capital Grand Est","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Financing","leadProduct":"ODI-2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Odimma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Odimma Therapeutics \/ Capital Grand Est","highestDevelopmentStatusID":"4","companyTruncated":"Odimma Therapeutics \/ Capital Grand Est"}]

    Find Clinical Drug Pipeline Developments & Deals by Odimma Therapeutics

    Menu

    Odimma Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Odimma Therapeutics

    France arrow
    BePharma
    Not Confirmed

    Odimma Therapeutics

    France arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ODI-2001

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Capital Grand Est

    Deal Size : $2.2 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Odimma Therapeutics Secures €2 Million to Complete the Preparation of Its First-in-Man Clinical Trial

    Details : The financing will secure the preparation on Odimma's First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer.

    Product Name : ODI-2001

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    February 05, 2023

    Lead Product(s) : ODI-2001

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Capital Grand Est

    Deal Size : $2.2 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Odimma Therapeutics

    France arrow
    BePharma
    Not Confirmed

    Odimma Therapeutics

    France arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ODI-2001

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : ABL Europe

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    ABL and Odimma Therapeutics Enter Development Agreement

    Details : ABL will manufacture the viral component of Odimma's innovative and proprietary immunization platform ODI-2001. The viral component present in ODI-2001 plays the role of both a strong immune adjuvant and of a carrier for the DNA vector expressing persona...

    Product Name : ODI-2001

    Product Type : Oligonucleotide

    Upfront Cash : Undisclosed

    May 17, 2022

    Lead Product(s) : ODI-2001

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : ABL Europe

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth